At Paragon Biosciences our philosophy is simple: start with what the patient needs, understand the science behind the disease and then build companies completely focused on addressing unmet needs. That is what drives our successful model of rational drug development which helps speed the approval of important medicines. More than 6,000 diseases today that do not have a treatment available. We will make that number smaller, and help patients live longer, better lives.
We develop companies with disciplined, targeted strategies that address specific clinical areas.
Castle Creek Pharma employs a unique strategy in selective asset identification and capital efficient development that is driving the company to become one of the industry’s most prolific developers of innovative and high potential late stage therapies for rare genetic dermatology conditions. For more information, please visit www.castlecreekpharma.com.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on therapies for sleep and cognitive disorders, Harmony’s goal is to push the boundaries of what science can do to improve the lives of patients. For more information, please visit www.harmonybiosciences.com.
Skyline Biosciences is developing first in-kind oncology therapies to treat premalignant and malignant conditions with unmet medical need. Skyline’s mission is to alleviate potentially life-threatening conditions and to improve the quality of life for the patients it serves.
Emalex is committed to developing effective treatments for the Central Nervous System (CNS). Emalex’s focus is on making lives easier for the courageous people living with CNS disorders.
Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.
Developing the latest therapies for those living with serious immunology conditions.